More specifically, these studies show that CD36 can promote the activation of the MAPK signaling pathway, upregulate protein expression of Bcl2 and cyclin D1 and engage with the TGF-β signaling for epithelial to mesenchymal transition (EMT) by cancer cells [30, 47]. The gene discussed is BCL2; the disease is cancer.